0000000000011472

AUTHOR

Juan Carlos Hernandez Boluda

showing 10 related works from this author

Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?

2017

Abstract Background There is a lack of clinical information regarding the usefulness of plasma Epstein-Barr virus (EBV) DNA load kinetics analyses in the management of EBV infections in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Namely, it remains unknown whether this type of analysis can help physicians to anticipate the development of high-level EBV DNAemia episodes requiring rituximab treatment or predict the risk of recurrent EBV DNAemia or post-transplant lymphoproliferative disorders (PTLDs). Study design Unicentric, retrospective, observational study including 142 consecutive patients undergoing T-cell replete allo-HSCT. The plasma EBV DNA load was mon…

Male0301 basic medicineEpstein-Barr Virus InfectionsHerpesvirus 4 HumanDna loadmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationPolymerase Chain ReactionVirus03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicinehemic and lymphatic diseasesVirologyClinical informationHumansTransplantation HomologousMedicineRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationEpstein-Barr virus DNAvirus diseasesViral Loadmedicine.diseaseTransplant RecipientsKinetics030104 developmental biologyInfectious DiseasesDNA ViralImmunologyFemaleRituximabReagent Kits DiagnosticAllogeneic hematopoietic stem cell transplantRituximabbusiness030215 immunologymedicine.drugJournal of Clinical Virology
researchProduct

Impact of Clinical Features, Cytogenetics, Genetic Mutations and Methylation of CDKN2B and DLC-1 Promoters on Treatment Response to Azacitidine

2019

Introduction : Azacitidine (AZA) is a DNA hypomethylating agent used in myeloid neoplasms, however approximately half of patients show treatment failure or relapse. Last years, several studies have showed that genetic mutations may influence on response and survival of the treated patients. Other biomarkers that have traditionally been associated with the response to AZA are the recovery of the platelet count and the presence of abnormalities in the chromosome 7. Finally, the methylation dynamics of genes promoters could be a useful tool to predict the clinical response. Aim: To assess the predictive value on response to AZA of clinical features, cytogenetics, genetic mutations and the meth…

Mutationmedicine.medical_specialtyImmunologyAzacitidineCytogeneticsPromoterCell BiologyHematologyMethylationBiologymedicine.diseasemedicine.disease_causeBiochemistrychemistry.chemical_compoundchemistryCDKN2BChromosome abnormalitymedicineCancer researchDNAmedicine.drugBlood
researchProduct

The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic s…

2018

Monitoring Torque teno virus (TTV) DNA load helps to estimate the risk of opportunistic infections in solid organ transplant recipients. We investigated whether the early kinetic pattern of plasma TTV DNA load after allogeneic hematopoietic stem cell transplantation (allo-HSCT) associates with subsequent CMV and EBV DNAemia. This study included 71 allo-HSCT patients. We found that the area under the curve (AUC) for log10 TTV DNA loads quantified by days 20 and 30 after transplantation (TTV DNA load AUC20-30), was significantly lower (P=0.036) in patients who subsequently developed CMV DNAemia requiring preemptive antiviral therapy (n=17) than in those who did not (n=8) or had no CMV DNAemia…

Male0301 basic medicineTorque teno virusTransplantation Conditioningmedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantation03 medical and health sciencesInterferonmedicineHumansRetrospective StudiesTorque teno virusTransplantationbusiness.industryHematopoietic Stem Cell TransplantationArea under the curvevirus diseasesHematologyCmv dnaemiaVirologyTransplantation030104 developmental biologyHematology; TransplantationCytomegalovirus InfectionsDNA ViralImmunologyFemaleTransplantation ConditioningbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoi…

2019

Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only curative treatment for myelofibrosis (MF), but its associated toxicity remains high. Prognostic risk models are widely used in clinical practice to select those MF patients who are more likely to benefit from transplantation. Recently, a new prognostic model, the Myelofibrosis Transplant Scoring System (MTSS), has been developed to predict the outcome of MF patients undergoing allo-HCT (Gagelmann N et al, Blood 2019). We aimed to evaluate the performance of such model in an independent series of patients. Methods: This is a retrospective study that included all adult patients who underwent first allo…

medicine.medical_specialtyUnivariate analysisbusiness.industryIncidence (epidemiology)ImmunologyRetrospective cohort studyCell BiologyHematologyBiochemistryTransplantationLog-rank testInternal medicineCohortmedicineCumulative incidencebusinessSurvival analysisBlood
researchProduct

rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signal…

2018

Abstract Introduction: Transformation to secondary myelofibrosis (MF) occurs as part of the natural history of polycythemia vera (PV) and essential thrombocythemia (ET), the two more indolent Ph-negative myeloproliferative neoplasms (MPN). Once transformed, survival is remarkably shorted. Chronic inflammation plays a critical role in the progression of MPN, driving clonal expansion toward end stage disease. Importantly, MPN are characterized by the production of inflammatory cytokines, by both malignant and non-malignant clone. Inflammation and cancer share a common pathway, i.e. NF-κB. Interestingly, miR-146a regulates TLR/NF-κB pathway through the inhibition of its targets, IRAK1 and TRAF…

Oncologymedicine.medical_specialtyeducation.field_of_studyEssential thrombocythemiabusiness.industrymedicine.medical_treatmentImmunologyPopulationSingle-nucleotide polymorphismCell BiologyHematologymedicine.diseaseBiochemistryProinflammatory cytokinePolycythemia veraCytokineInternal medicineGenotypemedicineMyelofibrosiseducationbusinessBlood
researchProduct

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

2018

Abstract Introduction: Over half of patients with chronic myeloid leukemia (CML) in sustained deep molecular remission do not lose the major molecular response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in controlled clinical trials, but there is scarce information on its applicability in the real-life setting. We aimed to assess if treatment cessation was feasible in clinical practice in a large nationwide series of CML patients from Spain. Methods: This retrospective study comprised a series of 236 patients in chronic-phase CML who discontinued TKI treatment outside of clinical trials between April 2009 and February 2018 in 33 Spanish insti…

0301 basic medicinemedicine.medical_specialtyUnivariate analysisbusiness.industryIncidence (epidemiology)ImmunologyCell BiologyHematologyBiochemistryDiscontinuationTransplantationClinical trial03 medical and health sciences030104 developmental biology0302 clinical medicineImatinib mesylateNilotinib030220 oncology & carcinogenesisInternal medicinemedicineCumulative incidencebusinessmedicine.drugBlood
researchProduct

Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogenei…

2021

Objective To compare the efficacy and safety of CD34+ selected ex vivo T-cell depletion (TCD) vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil (PTCy-Sir-MMF) as graft-vs-host disease (GVHD) prophylaxis. Methods We retrospectively included patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) with either TCD (n = 38) or PTCy-Sir-MMF (n = 91). Results Cumulative incidence of neutrophil and platelet recovery was 92% vs 99% (P = .06) and 89% vs 97% (P = .3) in TCD and PTCy-Sir-MMF, respectively. Cumulative incidences of aGHVD grade II-IV, III-IV, and moderate to severe cGVHD were 11% vs 19% (P = .2), 3% vs 2% (P = .9), and 3% vs 36% (P < …

Malemedicine.medical_treatmentT-LymphocytesCD34Graft vs Host DiseaseHematopoietic stem cell transplantationMycophenolateGastroenterologySeverity of Illness IndexLeukocyte Count0302 clinical medicineImmune ReconstitutionPostoperative ComplicationsRecurrenceGVHD prophylaxisAntineoplastic Combined Chemotherapy ProtocolsCumulative incidenceHematopoietic Stem Cell TransplantationT-cell depletionHematologyGeneral MedicineMiddle AgedPrognosisLeukemia Myeloid Acutesurgical procedures operativeTreatment OutcomeT-cell depletion030220 oncology & carcinogenesishematopoietic stem cell transplantationcardiovascular systemFemalemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideAdolescentLymphocyte Depletion03 medical and health sciencesYoung AdultInternal medicinemedicineHumansTransplantation HomologousGVHD prophylaxis T-cell depletion hematopoietic stem cell transplantation post-transplantation cyclophosphamideCyclophosphamideAgedPostoperative CareSirolimuspost-transplantation cyclophosphamidebusiness.industryMycophenolic AcidSirolimusbusinessEx vivoBiomarkers030215 immunologyEuropean journal of haematologyREFERENCES
researchProduct

Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting

2016

Summary Pathogenic interactions between bacteria and cytomegalovirus (CMV) may potentially occur early after allogeneic stem cell transplantation (Allo-SCT). This possibility nevertheless has not been investigated in depth. This was a retrospective study that included 170 consecutive patients who underwent 173 Allo-SCTs. Both bacterial infection (most of which were bacteremic) and CMV DNAemia were detected in 78 Allo-SCTs (62.9%). In total, 51 and 32 episodes of bacterial infection preceded or occurred after CMV DNAemia detection, respectively. Both events were diagnosed concurrently in four Allo-SCTs. The cumulative incidence of bacterial infection (of any type) over the study period was c…

AdultMale0301 basic medicineAdolescent030106 microbiologyCongenital cytomegalovirus infectionCytomegalovirusBacteremiaYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansTransplantation HomologousCumulative incidence030212 general & internal medicineAgedProportional Hazards ModelsRetrospective StudiesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesRetrospective cohort studyBacterial InfectionsCmv dnaemiaMiddle Agedmedicine.diseaseCytomegalovirus infectionTransplantationBacteremiaCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellbusinessFollow-Up StudiesTransplant International
researchProduct

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

2018

Abstract Introduction: Triple negative primary myelofibrosis (TN-PMF) and myelodysplastic syndromes with fibrosis (F-MDS) are rare entities, often difficult to distinguish each other. Currently, no specific molecular markers allowing a precise differential diagnosis are available. In this sense, next generation techniques (NGS) might be useful to distinguish between both entities and to refine prognosis. Methods: Thirty-nine patients with TN-PMF (n=16) or F-MDS (n=23) were analyzed, Targeted NGS was performed in 28 cases (10 TN-PMF and 18 F-MDS) using the Sophia Genetics Myeloid Tumor Solution Panel including the following genes: ABL1, ASXL1, BRAF, CALR, CBL,CEBPA, CSF3R,CSNK1A1,DNMT3A, ETV…

Oncologymedicine.medical_specialtyAcute leukemiaMyeloidbusiness.industryMyelodysplastic syndromesImmunologyCell BiologyHematologyGene mutationmedicine.diseaseBiochemistrymedicine.anatomical_structureInternal medicineCEBPAmedicineChromosome abnormalityHRASMyelofibrosisbusinessBlood
researchProduct

Excess Mortality in Polycythemia Vera and Essential Thrombocythemia

2018

Abstract Background and objective. An important proportion of patients with polycythemia vera (PV) and essential thrombocythemia (ET) are diagnosed in the seventh and eighth decades of life. Because of the chronic course of PV and ET and the advanced age of patients, many will actually die from age-related ailments instead of the myeloproliferative neoplasm, so the disease's impact on life-expectancy remains largely unknown. This registry‐based study was aimed at investigating the excess mortality attributable to PV and ET in a large series of patients diagnosed and managed according to modern criteria. Methods. We queried the databases of the Spanish Group for Chronic Myeloproliferative Ne…

Excess mortalityPediatricsmedicine.medical_specialtyeducation.field_of_studybusiness.industryEssential thrombocythemiaImmunologyPopulationCell BiologyHematologyDiseasemedicine.diseaseBiochemistryPolycythemia veraInterquartile rangeCohortMedicinebusinesseducationMyeloproliferative neoplasmBlood
researchProduct